Pharma outlook 2030: From evolution to revolution

Pharma outlook 2030: From evolution to revolution

Pharmaceutical companies need to radically change to survive and thrive in 2030.

1000

Director, Advisory

KPMG Australia

Contact

Also on KPMG.com

We believe that pharmaceutical revenues will fall well short of forecasts, as current projections, as well as business and operating models, do not reflect the turbulence in the marketplace.

Two seismic shifts are impacting the industry: the need to demonstrate value from therapies; and the move from treatment to prevention, diagnostics and cure, all of which is bringing in a host of new competitors.

To rise to this challenge, executive teams need to choose which of the following three ‘archetypes’ they want their organisation to become:

  1. Active pharmaceutical portfolio company
  2. Virtual value chain orchestrator
  3. Pharmaceutical niche specialist

Those pharmaceutical companies that manage to embrace the most appropriate archetypes, and master disruption, have the greatest chance to deliver real value to patients and be successful in the new, disrupted world.

Value-based pricing in pharmaceuticals – hype or hope?

Value-based pricing of pharmaceutical products can help improve patient outcomes – at an affordable cost.

 
Read more

Life Sciences

Life Sciences

KPMG's Life Sciences industry practice advises businesses from biotechnology start-ups to large multinational pharmaceutical companies.

Connect with us

 

Request for proposal

 

Submit

KPMG’s new-look website

KPMG has launched a state of the art digital platform that enhances your experience and provides improved access to our content and our people, whatever device you are on.

 
Read more